RPRX Stock Analysis: Buy, Sell, or Hold?
RPRX - Royalty Pharma plc Class A Ordinary Shares
$57.77
1.99 (3.57%)
▲
5d:
+5.63%
30d:
+6.96%
90d:
+19.14%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Accumulation
None View Scanner →
Strength: 4.6/10
Get Alerted When RPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RPRX shows positive signals but monitor for confirmation. Market pricing in 5.9% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: RPRX shows positive signals but monitor for confirmation. Market pricing in 5.9% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$67.96
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$42.20
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RPRX is currently trading at $57.77, which is considered extended relative to its 30-day fair value range of $53.90 to $56.04. From a valuation perspective, the stock is trading at a premium (Forward PE: 10.3) compared to its historical average (8.7). At these levels, the market is pricing in 5.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is approaching resistance at $57.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: RPRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is approaching resistance at $57.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: RPRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$53.90 -
$56.04
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.0%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- NEUTRAL: Near Wall St target ($59.25)
- NEUTRAL: Trading at premium valuation - market expects 5.9% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$53.90 -
$56.04
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$51.15
Resistance Level
$57.80
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.29
Wall Street Target
$59.25
(+2.6%)
Revenue Growth (YoY)
11.0%
Earnings Growth (YoY)
23.2%
Profit Margin
33.9%
Valuation Premium vs History
+5.9% premium
PE vs Historical
10.3 vs 8.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.9%
(market-implied from PE analysis)
1-Year Target
$61.18
(+6%)
2-Year Target
$64.79
(+12%)
3-Year Target
$68.61
(+19%)
3-Yr Target (if PE normalizes)
(PE: 10→9)
PE COMPRESSION
$58.01
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 9.7%)
$161.43
(+179%)
Base:
(SPY PE: 10.3, Growth: 9.7%)
$76.27
(+32%)
Bear:
(PE: 8.7, Growth: 9.7%)
$64.48
(+12%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (29x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 29.36 | Current EPS (TTM): $1.90
Bull Case
$122.72
(+112%)
Analyst growth 100.0%, PE expands to 32.3
Base Case
$111.56
(+93%)
Market implied 100.0%, PE stable at 29.4
Bear Case
$37.93
(-34%)
Severe decline -20.0%, PE contracts to 25.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 04, 2026 6:50 AM ET
Data refreshes hourly during market hours. Next update: 7:50 AM
Data refreshes hourly during market hours. Next update: 7:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Terrance P Coyne
SELL
34791 shares
2026-04-01
Terrance P Coyne
SELL
34791 shares
2026-03-23
Terrance P Coyne
SELL
34791 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 57 HOLD |
|
VERA
Vera Therapeutics Inc |
STRONG BUY
14 analysts |
$78 | 59 HOLD |
Advanced RPRX Option Strategies
Professional options setups generated by AI based on today's RPRX price and gamma walls.
